Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 28;24(13):10767.
doi: 10.3390/ijms241310767.

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Elisabetta Cocconcelli  1 , Nicol Bernardinello  1 , Gioele Castelli  1 , Simone Petrarulo  1 , Serena Bellani  1 , Marina Saetta  1 , Paolo Spagnolo  1 , Elisabetta Balestro  1
Affiliations
Review

Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis

Elisabetta Cocconcelli et al. Int J Mol Sci. .

Abstract

Sarcoidosis is a multisystemic disease of unknown etiology characterized by the formation of granulomas in various organs, especially lung and mediastinal hilar lymph nodes. The clinical course and manifestations are unpredictable: spontaneous remission can occur in approximately two thirds of patients; up to 20% of patients have chronic course of the lung disease (called advanced pulmonary sarcoidosis, APS) resulting in progressive loss of lung function, sometimes life-threatening that can lead to respiratory failure and death. The immunopathology mechanism leading from granuloma formation to the fibrosis in APS still remains elusive. Recent studies have provided new insights into the genetic factors and immune components involved in the clinical manifestation of the disease. In this review we aim to summarize the clinical-prognostic characteristics and molecular pathways which are believed to be associated with the development of APS.

Keywords: advanced pulmonary fibrosis; molecular pathway; sarcoidosis; signaling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Spagnolo P., Rossi G., Trisolini R., Sverzellati N., Baughman R.P., Wells A.U. Pulmonary Sarcoidosis. Lancet Respir. Med. 2018;6:389–402. doi: 10.1016/S2213-2600(18)30064-X. - DOI - PubMed
    1. Travis W.D., Costabel U., Hansell D.M., King T.E., Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
    1. Raghu G., Rochwerg B., Zhang Y., Garcia C.A.C., Azuma A., Behr J., Brozek J.L., Collard H.R., Cunningham W., Homma S. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015;192:e3–e19. doi: 10.1164/rccm.201506-1063ST. - DOI - PubMed
    1. Cottin V. Treatment of Progressive Fibrosing Interstitial Lung Diseases: A Milestone in the Management of Interstitial Lung Diseases. Eur. Respir. Soc. 2019;28:190109. doi: 10.1183/16000617.0109-2019. - DOI - PMC - PubMed
    1. Kolb M., Vašáková M. The Natural History of Progressive Fibrosing Interstitial Lung Diseases. Respir. Res. 2019;20:57. doi: 10.1186/s12931-019-1022-1. - DOI - PMC - PubMed

MeSH terms